<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(44)</volume><submitter>Yoon YS</submitter><pubmed_abstract>The evaluation of therapeutic efficacy is necessary to predict the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive chemosensitivity assays and biomarkers to optimize efficacy and minimize toxicity. The introduction of targeted agents has improved the progression-free survival and overall survival of patients with metastatic disease. However, approximately 50% of patients do not show a positive response to chemotherapy and the selection of patients likely to respond to a specific regimen remains challenging. Cell culture-based chemosensitivity tests use autologous viable tumor cells to evaluate susceptibility to specific agents in vitro and predict their direct effects. Adenosine triphosphate-based assays and methyl thi</pubmed_abstract><journal>World journal of gastroenterology</journal><pagination>16398-408</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4248183</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Recent applications of chemosensitivity tests for colorectal cancer treatment.</pubmed_title><pmcid>PMC4248183</pmcid><pubmed_authors>Yoon YS</pubmed_authors><pubmed_authors>Kim JC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Recent applications of chemosensitivity tests for colorectal cancer treatment.</name><description>The evaluation of therapeutic efficacy is necessary to predict the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive chemosensitivity assays and biomarkers to optimize efficacy and minimize toxicity. The introduction of targeted agents has improved the progression-free survival and overall survival of patients with metastatic disease. However, approximately 50% of patients do not show a positive response to chemotherapy and the selection of patients likely to respond to a specific regimen remains challenging. Cell culture-based chemosensitivity tests use autologous viable tumor cells to evaluate susceptibility to specific agents in vitro and predict their direct effects. Adenosine triphosphate-based assays and methyl thi</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Nov</publication><modification>2025-05-31T23:43:33.212Z</modification><creation>2019-03-27T01:40:30Z</creation></dates><accession>S-EPMC4248183</accession><cross_references><pubmed>25469008</pubmed><doi>10.3748/wjg.v20.i44.16398</doi></cross_references></HashMap>